Vantis Vascular, a San Jose, CA-based medical technology company, raised $10M in Series B-1 Funding, following a raise of $30M to date from high-net-worth individuals and National Institute of Health grants.
Led by CEO Jason Turner, Vantis Vascular is a medical technology company dedicated to improving vascular interventions. With a focus on innovation and patient-centric solutions, the company is committed to advancing the field of interventional cardiology and improving patient outcomes worldwide.
Vantis intends to use the funds to initiate US commercialization of its CrossFAST™ Integrated Microcatheter Advanced Delivery System.
The CrossFAST System is a dual monorail microcatheter advanced delivery system purpose-built for complex coronary and peripheral interventions, which incorporates an integrated microcatheter with a seamless transition to lower the risk of these adverse events during catheter delivery.
The CrossFAST System is empowered by DuoPRO™ Interlocking Technology, a new mechanism coupling the microcatheter to the outer delivery catheter, allowing the system to be advanced as one unit for enhanced pushability and efficient navigation, a significant limitation of guide extension catheters, especially in complex high-risk procedures.
The system is commercially available in the United States as part of a limited market release. Full market release is planned in 2025.
